ID   Kasumi-4
AC   CVCL_0613
SY   KASUMI-4; Kasumi 4
DR   CLO; CLO_0007071
DR   ATCC; CRL-2726
DR   BioSample; SAMN03471778
DR   DSMZ; ACC-715
DR   DSMZCellDive; ACC-715
DR   GEO; GSM4254132
DR   JCRB; JCRB0161
DR   JCRB; NIHS0237
DR   Wikidata; Q54899521
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8611478;
RX   PubMed=10071072;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=32180206;
CC   Population: Japanese.
CC   Doubling time: ~55 hours (PubMed=8611478).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=32180206).
CC   Omics: Variations; SNP array analysis.
CC   Discontinued: DSMZ; ACC-715; true.
CC   Discontinued: JCRB; NIHS0237; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC=CRL-2726; DSMZ=ACC-715; JCRB=JCRB0161
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,12
ST   D16S539: 9,13
ST   D18S51: 13,16
ST   D19S433: 15
ST   D21S11: 29,30
ST   D2S1338: 20,23
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 11,13
ST   FGA: 19,23
ST   Penta D: 9,14
ST   Penta E: 16,17
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C7320; Childhood chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   6Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 28
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=8611478; DOI=10.1046/j.1365-2141.1996.4821023.x;
RA   Asou H., Eguchi M., Suzukawa K., Morishita K., Tanaka K., Date M.,
RA   Hamamoto K., Kamada N.;
RT   "Establishment of a myeloid leukaemia cell line (Kasumi-4) with
RT   t(9;22;11)(q34;q11;q13), inv(3)(q21q26) and the EVI1 gene activation
RT   from a patient with chronic myelogenous leukaemia in blast crisis.";
RL   Br. J. Haematol. 93:68-74(1996).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000), 255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=32180206; DOI=10.1007/s13577-020-00347-5; PMCID=PMC7324421;
RA   Kasai F., Asou H., Ozawa M., Kobayashi K., Kuramitsu H., Satoh M.,
RA   Kohara A., Kaneko Y., Kawamura M.;
RT   "Kasumi leukemia cell lines: characterization of tumor genomes with
RT   ethnic origin and scales of genomic alterations.";
RL   Hum. Cell 33:868-876(2020).
//